Cyclacel Pharmaceuticals (NASDAQ:CYCC) Getting Somewhat Negative Press Coverage, Study Finds
Press coverage about Cyclacel Pharmaceuticals (NASDAQ:CYCC) has been trending somewhat negative this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cyclacel Pharmaceuticals earned a daily sentiment score of -0.15 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 96 out of 100, indicating that recent press coverage is extremely likely to have an impact on the stock’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Company Watch: Stock Nearing 52-Week Low Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – Sparta Review (spartareview.com)
- Cyclacel Pharmaceuticals, Inc. (CYCC) stock RSI moves to 23.07 – Voice Of Analysts (analystsbuzz.com)
- Needle Action Activity Spotted in Cyclacel Pharmaceuticals Inc (CYCC) – Wall Street Review (thewallstreetreview.com)
- Nasopharyngeal Cancer Market Size to Observe Steady Growth by 2022 (sbwire.com)
- RSI Alert: Cyclacel Pharmaceuticals, Inc. (CYCC) Now Oversold – Voice Of Analysts (analystsbuzz.com)
Shares of Cyclacel Pharmaceuticals (CYCC) traded down 3.84% during trading on Friday, hitting $3.51. The stock had a trading volume of 95,022 shares. Cyclacel Pharmaceuticals has a 1-year low of $3.05 and a 1-year high of $10.90. The firm’s 50 day moving average is $4.52 and its 200 day moving average is $4.75.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.38) earnings per share for the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 72.48% and a negative net margin of 1,128.13%. Analysts expect that Cyclacel Pharmaceuticals will post ($2.25) earnings per share for the current year.
Separately, Zacks Investment Research lowered Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, April 26th.
COPYRIGHT VIOLATION NOTICE: “Cyclacel Pharmaceuticals (NASDAQ:CYCC) Getting Somewhat Negative Press Coverage, Study Finds” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/07/16/cyclacel-pharmaceuticals-cycc-earning-somewhat-critical-press-coverage-analysis-shows-updated-updated-updated.html.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.
Receive News & Stock Ratings for Cyclacel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.